•  
  •  
  •  
  •  

2025-09-03 03:57:06

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes

Keywords Selected:  SuvenLifeSciences

Stock Report

  • Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant
  • Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant
  • Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant
  • Suven Life Sciences Ltd Q1 FY25 consolidated loss at Rs. 28.03 crores
  • Suven Life Sciences Ltd Q4 FY24 consolidated loss at Rs. 26.54 crores
  • Suven Life Sciences to present Phase-2 Positive Results on Samelisant at American Academy of Neurology2024 Annual Meeting, Denver, USA
  • Suven Life Sciences Ltd reports consolidated loss of Rs. 12.68 crores in Q2 FY2024
  • Suven Life Sciences Ltd Q1 FY24 consolidated loss at Rs. 24.09 crores
  • Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
  • Suven Lifesciences Ltd consolidated Q4FY23 loss at Rs. 27.64 crores
  • Suven Life Sciences Ltd Q3FY23 consolidated loss increases to Rs. 51.11 crores
  • Suven Life Sciences announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine
  • Suven Life Sciences Ltd consolidated Q2FY23 loss at Rs. 23.18 crores
  • Suven Life Sciences Limited approves 1:2 rights issue
  • Suven Life Sciences Ltd Q1FY23 consolidated loss at Rs. 16.32 crores
  • Suven Life Sciences Ltd approves rights issue of Rs. 400 crores
  • Suven Life Sciences Ltd Board to consider Right Issue of equity shares
  • Suven Life Sciences posts Q4FY22 consolidated loss of Rs. 20.79 crores
  • Suven Life Sciences Limited allots 1,81,00,000 shares
  • Suven Life Sciences reports consolidated loss of Rs. 33.69 crores in Q3FY22
  • Suven Life Sciences Ltd Q2FY22 consolidated loss at Rs. 28.29 crore

Latest Post

  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024